Pharmaceutical giant Sanofi announced on June 10 that it has discontinued a major clinical trial for its experimental drug riliprubart following disappointing interim results that indicated the treatment would not demonstrate adequate effectiveness.
The discontinued study, known as the MOBILIZE trial, was testing riliprubart as a potential treatment for chronic inflammatory demyelinating polyneuropathy, specifically targeting patients who had not responded to conventional therapies for this rare neurological disorder.
According to the company’s announcement, an independent data monitoring committee conducted the interim review and determined no safety concerns were associated with the experimental treatment during their analysis.
Sanofi indicated it will now assess whether to continue other ongoing studies involving riliprubart, including another Phase 3 trial called VITALIZE.
The pharmaceutical company stated that ending this trial will not result in substantial financial losses or alter its projected financial outlook for 2026.
